Prof David Bowtell
Honorary Conjoint Professorial Fellow
The Sir Peter MacCallum Department of Oncology
567 Scholarly works
60 Projects
HIGHLIGHTS
2024
Journal article
BRCA1 secondary splice-site mutations drive exon-skipping and PARP inhibitor resistance
DOI: 10.1186/s12943-024-02048-12022
Research grants (ARC, NHMRC, MRFF)
Driving Improvements in Ovarian Cancer Survival Through Molecular and Clinical Studies
2020
Research grants (ARC, NHMRC, MRFF)
Evaluation of Fibroblastic Activation Protein Inhibitors (FAPI) as a Novel Radiopharmaceutical Targeting Cancer-Associated Fibroblasts for the Diagnosis and Treatment of Patients With Cancer of Unknown Primary: The FAPI-CUP Trial
2018
Journal article
Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma
DOI: 10.1038/s41467-018-05564-z2017
Journal article
Secondary somatic mutations restoring RAD51C and RAD51D associated with acquired resistance to the PARP inhibitor rucaparib in high-grade ovarian carcinoma
DOI: 10.1158/2159-8290.CD-17-04192017
Research Grant
Acrf Tumour Heterogeneity Program
2016
Journal article
Pericytes promote malignant ovarian cancer progression in mice and predict poor prognosis in serous ovarian cancer patients
DOI: 10.1158/1078-0432.CCR-15-1931
RECENT SCHOLARLY WORKS
2026
Journal article
Clinicopathologic and molecular predictors of survival in BRCA-deficient tubo-ovarian high-grade serous carcinoma
DOI: 10.1038/s41467-026-71134-32026
Journal article
"TRACEBACK has probably saved my life": experiences of being notified about clinically significant cancer genetic information by the Australian TRACEBACK program.
DOI: 10.1016/j.gim.2026.1027702026
Journal article
Using Polygenic Risk Scores to Refine Risk and Outcomes in High-grade Serous Ovarian Cancer in Australia.
DOI: 10.1158/1055-9965.EPI-25-18822026
Other
Supplementary Tables 1-16 from Using Polygenic Risk Scores to Refine Risk and Outcomes in High-grade Serous Ovarian Cancer in Australia
DOI: 10.1158/1055-9965.340411872026
Other
Supplementary Figure 12 from Using Polygenic Risk Scores to Refine Risk and Outcomes in High-grade Serous Ovarian Cancer in Australia
DOI: 10.1158/1055-9965.340412142026
Other
Supplementary Figure 5 from Using Polygenic Risk Scores to Refine Risk and Outcomes in High-grade Serous Ovarian Cancer in Australia
DOI: 10.1158/1055-9965.340412022026
Other
Supplementary Figure 10 from Using Polygenic Risk Scores to Refine Risk and Outcomes in High-grade Serous Ovarian Cancer in Australia
DOI: 10.1158/1055-9965.340412202026
Other
Supplementary Figure 11 from Using Polygenic Risk Scores to Refine Risk and Outcomes in High-grade Serous Ovarian Cancer in Australia
DOI: 10.1158/1055-9965.34041217